- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07946367
Dual-targeting of B & T Cell Pathways Evaluation Trial (DUET)
Evaluation of Safety, Treatment Response and Biological Effects of DFI205 in Systemic Autoimmune Rheumatic Diseases (SARDs); a Phase 1/2a First-in-Human (FIH) Study
This is a first-in-human study of DFI205, an investigational bispecific antibody that binds CD20 and CD40, with the goal of targeting both B- and T-cell function in adults with active systemic autoimmune rheumatic diseases (SARDs) despite standard therapy. In Phase 1, participants with RA, SLE, SSc or IIM will receive a single dose at increasing dose levels to establish safety and initial treatment response. The selected dose will be carried forward into Phase 2a, where participants will receive monthly doses to assess safety and treatment response.
연구 개요
상태
개입 / 치료
연구 유형
등록 (추정된)
단계
- 2 단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Bernhard Remes
- 전화번호: 0049641944360
- 이메일: info@diabetesfree.com
연구 장소
-
-
-
Erlangen, 독일, 91054
- 모병
- Universitaetsklinikum Erlangen AöR
-
연락하다:
- Georg Schett
- 전화번호: 00499131-85-32093
- 이메일: Studienambulanz.M3@uk-erlangen.de
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male and female participants, age 18 years and older.
- Able to understand and comply with all scheduled visits, treatment plans, laboratory tests, and other procedures of the study protocol including ability to provide written informed consent.
- Maintaining a stable, qualifying, standard of care regimen for ≥4 weeks prior to screening as treatment for a qualifying primary diagnosis (RA, SLE, SSc, IIM including the disease-specific criteria listed below):
- Rheumatoid Arthritis (RA) participants must have, 1) positivity of anti-citrullinated protein antibody (ACPA) and/or rheumatoid factor (RF); 2) moderate to highly active disease despite treatment with at least 2 lines of standard therapy; 3) disease duration ≥ 6 months; secondary Sjögren's disease diagnosis is acceptable as long as other criteria are met.
- Systemic Lupus Erythematosus (SLE) participants must have, 1) positivity of anti-nuclear-antibodies (ANA) and/or anti-dsDNA and/or anti-histone and/or anti-nucleosome and/or anti-Sm antibodies; 2) active disease despite treatment with at least 2 lines of standard therapy; 3) disease duration ≥ 6 months.
- Systemic Sclerosis (SSc) participants must have, 1) positivity for at least one SSc-associated autoantibody; 2) mRSS score >10 units or interstitial lung disease (ILD) including clinically relevant pulmonary involvement despite treatment with at least 2 lines of standard therapy; 3) disease duration ≤ 5 years (from onset of first non-Raynaud manifestation); 4) not eligible for or declining autologous hematopoietic stem-cell transplantation
- Idiopathic Inflammatory Myopathies (IIM) participants must have, 1) positivity for at least one myositis-specific antibody; 2) active myositis or presence of ILD defined by clinically relevant pulmonary involvement despite treatment with at least 2 lines of standard therapy; 3) disease duration ≥ 6 months
Exclusion Criteria:
- Diagnosis of a non-rheumatic autoimmune disease requiring therapeutic or investigational immune therapy or modulation (e.g., neuropathy requiring IVIg, Multiple Sclerosis). Milder autoimmune conditions requiring replacement or exocrine functional therapies are acceptable (e.g., Type 1 diabetes, Celiac Disease, Autoimmune Thyroid Disease if on stable treatment for at least 6 months).
- History of any pre-existing liver disease, including cirrhosis, acute liver disease, or chronic liver disease (unless considered stable for >6 months and required screening laboratory tests meet criteria).
- Severe unresolved cardiac disease.
- Estimated glomerular filtration rate (GFR) <30 mL/min/1.73 m2.
- Presence or history of active infections, including hepatitis B, hepatitis C, human immunodeficiency virus (HIV), Human T-lymphotropic virus (HTLV) or tuberculosis. Participants with laboratory evidence of active infection are excluded even in the absence of clinical evidence of active infection. Participants with mild skin and nail fungal infections are not excluded.
- Acute infection requiring systemic therapy or hospitalization within 30 days before screening.
- Invasive aspergillus, histoplasmosis, or coccidioidomycosis infection within one year prior to enrollment.
- Any history of malignancy in the 5 years before screening except for completely resected squamous or basal cell carcinoma of the skin.
- Primary or secondary immunodeficiency, including hypogammaglobulinemia.
- History or evidence of progressive multifocal leukoencephalopathy (PML) or other demyelinating disorders.
- Allergies to humanized monoclonal antibodies or severe post-treatment hypersensitivity reactions other than localized injection site reaction, to any biological molecule.
- Systemic corticosteroid therapy or adrenocorticotropic hormone (ACTH) use within 30 days prior to screening and within entire duration of screening period prior to beginning of study treatment, unless prescribed as background therapy.
- Intolerance of or contraindication to oral or IV corticosteroids.
- Treatment with other biologic or non-biologic immunosuppressant agents (e.g., anti-CD20 therapies, TNF inhibitors, azathioprine, cyclosporine, methotrexate, or mycophenolate) within 6 months prior to screening, unless prescribed as background therapy.
- The participant has taken another investigational drug within 3 months or 5-half-lives before the screening visit, whichever is longer, or any investigational drug that has depleted a cell type or line without recovery.
- Previous treatment with anti-CD19 agents, anti-CD38 agents, bispecific anti-CD19/CD3 T cell engaging therapies, adoptive T cell therapy or any prior gene therapy product.
- Received any form of stem cell transplant.
- Administration of live attenuated vaccine(s) within 12 weeks prior to and 12 weeks after the completion of DFI205 administration or any planned receipt during the study that cannot be delayed. Vaccinations should be up-to-date as per local clinical practice.
- Plasmapheresis within 3 months prior to first dose of DFI205
- Positive pregnancy test, presently breast-feeding, (female participants) or unwillingness to use highly effective contraceptive measures for the duration of the study and 6 months after discontinuation.
- Any condition, including the presence of relevant abnormalities in vital parameters or laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Phase 1 Single Ascending Dose Escalation
Intravenous (IV) infusion of DFI205 at ascending dose levels. |
A bispecific monoclonal antibody that binds to both CD20 and CD40 receptors on cells. |
|
실험적: Phase 2a Multi-Dose
DFI205 monthly IV infusions at the recommended Phase 2 dose |
A bispecific monoclonal antibody that binds to both CD20 and CD40 receptors on cells. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
To evaluate the initial safety and tolerability of DFI205 in adults with SARDs
기간: Up to 1 year post-dosing
|
Numbers and types of all adverse events (AEs) and serious adverse events (SAEs) |
Up to 1 year post-dosing
|
|
To monitor immune reconstitution after completion of dosing with DFI205
기간: Up to 1 year post-dosing
|
Time to normalized peripheral blood B cell counts compared to baseline. |
Up to 1 year post-dosing
|
|
To monitor immune response to DFI205
기간: Up to 1 year post-dosing
|
Number of participants with anti-drug antibody development. |
Up to 1 year post-dosing
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
To evaluate the ability of DFI205 to induce an objective response in adults with RA
기간: 24 weeks post-dosing
|
Overall Response Rate (ORR) measured by proportion of participants achieving either low-disease activity (DAS28-CRP ≤ 3.2, DAS28-ESR ≤3.2, SDAI≤11, CDAI≤10) or remission criteria (DAS28-CRP < 2.6, DAS28-ESR <2.6, SDAI ≤3.3, CDAI ≤ 2.8,Boolean 2.0 remission criteria) combined |
24 weeks post-dosing
|
|
To evaluate the ability of DFI205 to induce an objective response in adults with SLE
기간: 24 weeks post-dosing
|
Overall Response Rate (ORR) measured by fulfillment of DORIS remission criteria |
24 weeks post-dosing
|
|
To evaluate the ability of DFI205 to induce an objective response in adults with SSc
기간: 24 weeks post-dosing
|
Overall Response Rate (ORR) measured by proportion of participants achieving either modified Rodnan Skin Score (mRSS) decrease of >5 points and ≥ 25% decrease from baseline or no progression of interstitial lung disease (ILD progression defined as FVC decline >10%, or 5-10% plus worsening respiratory symptoms or HRCT progression) combined |
24 weeks post-dosing
|
|
To evaluate the ability of DFI205 to induce an objective response in adults with IIM
기간: 24 weeks post-dosing
|
Overall Response Rate (ORR) measured by achievement of major response (ACR/EULAR 2016 Myositis Response Criteria Total Improvement Score ≥ 60) |
24 weeks post-dosing
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
To evaluate the ability of DFI205 to reduce disease activity in adults with RA
기간: 24 weeks post-dosing
|
Change in tender joint count (TJC28) compared to baseline |
24 weeks post-dosing
|
|
To evaluate the ability of DFI205 to reduce disease activity in adults with RA
기간: 24 weeks post-dosing
|
Change in swollen joint count (SJC28) compared to baseline |
24 weeks post-dosing
|
|
To evaluate the ability of DFI205 to reduce disease activity in adults with SLE
기간: 24 weeks post-dosing
|
Change in British Isles Lupus Assessment Group (BILAG-2004) score compared to baseline |
24 weeks post-dosing
|
|
To evaluate the ability of DFI205 to reduce disease activity in adults with SSc
기간: 24 weeks post-dosing
|
Change in mRSS (0=no thickening, 3=severe thickening) compared to baseline |
24 weeks post-dosing
|
|
To evaluate the ability of DFI205 to reduce disease activity in adults with IIM
기간: 24 weeks post-dosing
|
Change in creatine phosphokinase (CPK) compared to baseline |
24 weeks post-dosing
|
|
To evaluate the ability of DFI205 to reduce disease activity in adults with IIM
기간: 24 weeks post-dosing
|
Change in muscle strength (MMT8 score) compared to baseline |
24 weeks post-dosing
|
|
To evaluate change in erythrocyte sedimentation rate (ESR) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
기간: Up to 1 year post-dosing
|
Up to 1 year post-dosing
|
|
|
To evaluate change in C-reactive protein (CRP) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
기간: Up to 1 year post-dosing
|
Up to 1 year post-dosing
|
|
|
To evaluate change in interleukin-6 (IL-6) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
기간: Up to 1 year post-dosing
|
Up to 1 year post-dosing
|
|
|
To evaluate change in tumor necrosis factor-alpha (TNF-α) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
기간: Up to 1 year post-dosing
|
Up to 1 year post-dosing
|
|
|
To investigate the pharmacokinetics of DFI205
기간: Up to 1 year post-dosing
|
Blood samples will be collected to quantitate serum concentrations of DFI205 |
Up to 1 year post-dosing
|
|
To investigate the pharmacodynamics of DFI205 in blood
기간: Up to 1 year post-dosing
|
Proportions of immune cell subsets in blood by FACS analysis over the course of the study. |
Up to 1 year post-dosing
|
|
To investigate the secondary lymphoid system pharmacodynamics of DFI205
기간: Up to 1 year post-dosing
|
Proportions of disease-specific lymph node cell populations over the course of the study. |
Up to 1 year post-dosing
|
|
To investigate soluble CD40 pharmacodynamics of DFI205
기간: Up to 1 year post-dosing
|
Soluble CD40 receptor/ligand blood concentrations over the course of the study treatments. |
Up to 1 year post-dosing
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Georg Schett, M.D., University of Erlangen-Nürnberg
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 2026TXSARD01
- 2026-526672-24-00 (씨티스)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .